MARC details
000 -LEADER |
fixed length control field |
03008cam a2200541 i 4500 |
001 - CONTROL NUMBER |
control field |
ocn868975208 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
OCoLC |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20240729131412.0 |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION |
fixed length control field |
m d |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr ||||||||||| |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
130816t20132013nyua ob 001 0 eng |
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
LC control number |
2019722594 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
DLC |
015 ## - NATIONAL BIBLIOGRAPHY NUMBER |
National bibliography number |
GBB3B8580 |
Source |
bnb |
016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
Record control number |
016589591 |
Source |
Uk |
019 ## - |
-- |
867904138 |
-- |
923672992 |
-- |
928194929 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9781629480633 |
Qualifying information |
ebook |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
1629480630 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
Cancelled/invalid ISBN |
9781629480480 |
Qualifying information |
pbk. |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
Cancelled/invalid ISBN |
1629480487 |
Qualifying information |
pbk. |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
662151 |
-- |
(N$T) |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
(OCoLC)868975208 |
Canceled/invalid control number |
(OCoLC)867904138 |
-- |
(OCoLC)923672992 |
-- |
(OCoLC)928194929 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED |
Subject category code subdivision |
071000 |
Source |
bisacsh |
049 ## - LOCAL HOLDINGS (OCLC) |
Holding library |
MAIN |
245 00 - TITLE STATEMENT |
Title |
Carbamazepine : |
Subtitle |
medical uses, pharmacokinetics and adverse effects |
Statement of responsibility, etc |
|
Medium |
[E-Book] |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
New York : |
Name of producer, publisher, distributor, manufacturer |
Nova Biomedical, |
Date of production, publication, distribution, manufacture, or copyright notice |
[2013] |
300 ## - PHYSICAL DESCRIPTION |
Physical description |
1 online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
490 1# - SERIES TITLE |
Series statement |
Pharmacology - research, safety testing and regulation |
504 ## - BIBLIOGRAPHY, ETC. NOTE |
Bibliography, etc |
Includes bibliographical references and index. |
505 0# - CONTENTS |
Contents |
Ch. I Carbamazepine Pharmacokinetic and Drug Interactions in Poly-Treated Patients / Swati Jaiswal -- ch. II Effect of Carbamazepine and Related Compounds on Ligand-Gated Ion Channels: Possible Implications for Synaptic Transmission and Side Effects / Andrea Becchetti -- ch. III Carbamazepine and its Derivatives: What's the Difference? / Emilio Russo -- ch. IV Clinical Use of Carbamazepine in Neurological Non-Epileptic Diseases / Antonio Siniscalchi -- ch. V Environmental Fate and Remediation of Carbamazepine in the Hydrosphere / J. Arturo Santaballa. |
520 ## - ABSTRACT |
Abstract |
Carbamazepine (CBZ), one of the most used antiepileptic drugs (AEDs), was introduced on the market in the early 1960's and ever since, it has become the most frequently prescribed drug for the treatment of several forms of epilepsy. It is also used to treat other pathologies, such as neuropathic pain and psychiatric disorders. This book provides a detailed description of this drug, evaluating all aspects of its pharmacology. CBZ pharmacokinetics is discussed, with a particular emphasis on its metabolism, side effects and drug interactions. Then the authors focus on its pharmacodynamic effects, |
590 ## - LOCAL NOTE (RLIN) |
Local note |
Master record variable field(s) change: 050, 082 |
650 #0 - SUBJECT HEADINGS |
Subject term |
Carbamazepine. |
9 (RLIN) |
5505 |
650 #0 - SUBJECT HEADINGS |
Subject term |
Anticonvulsants. |
9 (RLIN) |
5238 |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Gallelli, Luca, |
Relator term |
editor of compilation. |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Pharmacology - research, safety testing and regulation. |
856 ## - ONLINE RESOURCE |
Uniform Resource Identifier |
<a href="#gotoholdings">#gotoholdings</a> |
Link text |
Access resource |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Suppress in OPAC |
Do not Suppress in OPAC |
588 ## - SOURCE OF DESCRIPTION NOTE |
Source of description note |
Description based on print version record. |
938 ## - |
-- |
YBP Library Services |
-- |
YANK |
-- |
11319952 |
938 ## - |
-- |
EBSCOhost |
-- |
EBSC |
-- |
662151 |
938 ## - |
-- |
ebrary |
-- |
EBRY |
-- |
ebr10792499 |
938 ## - |
-- |
ProQuest Ebook Central |
-- |
EBLB |
-- |
EBL2145951 |
994 ## - |
-- |
92 |
-- |
N$T |